|Page (1) of 1 - 02/08/12||email article||print page|
Recombinant Data Named Finalist in Personalized Medicine World Conference 2012 "Most Promising Company" CompetitionClinical Data Warehousing and Intelligence Solutions Provider Only Software Company Selected (February 08, 2012)
NEWTON, MA -- (Marketwire) -- 02/08/12 -- Recombinant Data, a healthcare data warehousing and clinical intelligence solutions provider, today announced that it was a finalist in the Most Promising Company Competition at the Personalized Medicine World Conference 2012 (PMWC). The award is presented by PMWC and Prescience International. Recombinant was selected from among 31 entrants and was the only software company among the top three finalists which included biotech companies Auxogyn and Epizyme. Winners were selected by a panel of judges and attendee voting.
According to Tal Behar, co-founder of PMWC, the Competition showcases some of the world's most promising personalized medicine innovations. "Customization of treatment, with all decisions and practices being tailored to the individual, will be a revolution of the current healthcare cycle. We look forward to seeing how the companies highlighted during this year's Competition will define the next generation of personalized medicine," said Behar.
The PMWC 2012 Most Promising Company award is conferred to companies with technology, products or services that are disruptive and innovative to the current standard-of-care, both in cost and effectiveness; strength of team and ability to execute; barriers to competition and strength of intellectual property; and expected financial returns for investors.
"Being a finalist in the Most Promising Company Competition highlights Recombinant Data's success in providing critical data infrastructure and analytics solutions to leading pharma and biotech companies, academic medical centers and healthcare delivery systems," said Peter Emerson, CEO of Recombinant Data. "Linking data from patient care, clinical research and basic life science research and having the ability to analyze and interpret that data is essential to advancing personalized medicine. Recombinant Data is committed to this goal."
"We congratulate Recombinant Data and all of the companies competing this year," said Melinda Richter, founder and CEO, Prescience International. "The quality of entries demonstrates that personalized medicine will play an increasingly significant role in delivering high-quality, cost-effective healthcare and it will continue to grow in importance as scientific breakthroughs are translated into a new generation of targeted therapeutics."
About Recombinant Data Corp.
Recombinant provides leading-edge data warehousing and clinical intelligence solutions to healthcare providers, academic medical centers and life science researchers to deliver higher quality outcomes, accelerate personalized medicine, and lower costs. Our team of industry veterans is focused on improving the flow of reliable data to power clinical and research applications in a secure, compliant environment. For more information about Recombinant's products and services, visit www.recomdata.com.
About Personalized Medicine World Conference
The Personalized Medicine World Conference, a two-day business and educational conference that provides real-world insights on how to succeed in producing and implementing personalized medicine, is produced by PMWC International is dedicated to transforming healthcare through the global adoption of personalized medicine.
About Prescience International
Prescience International is dedicated to accelerating the commercialization and global adoption of science and technology. With industry expertise in the future of technology markets, Prescience International creates and manages centers of excellence in the form of research parks, innovation centers, research foundations, research institutes and emerging companies.
Copyright @ Marketwire
Related Keywords: Recombinant, personalized medicine, healthcare, data warehousing, clinical data, intelligence, Marketwire, , Financial, Biology, Business, Science,